Alpha-4 Integrin Inhibitors: A Divided Safety Profile

Generated September 2026 · Clinical Deep Dive0 CommentsTwo monoclonal antibodies interrupt the same family of leukocyte adhesion molecules, yet only one carries a boxed warning for a risk capable of ending a patient's life. Natalizumab (Tysabri, Tyruko) and vedolizumab (Entyvio) both block α4-integrin–mediated trafficking of lymphocytes into inflamed tissue, but natalizumab blocks both α4β1 and α4β7 integrins, crossing into the central nervous system and unlocking progressive multifocal leukoencephalopathy (PML) as a lifelong risk, while vedolizumab's selectivity for α4β7 keeps its action largely confined to the gut. Tysabri PI +1This is not an abstract distinction. No confirmed cases of PML have occurred in a vedolizumab-treated patient without another clear source of immunosuppression. Entyvio PI Natalizumab, over more than two decades of use, has produced a well-characterized, anti-JC virus antibody–stratified PML risk that reaches roughly 7 per 1,000 patients in the highest-risk stratum (antibody-positive, prior immunosuppressant use, 49–72 months of exposure). Tysabri PI Vedolizumab, for its part, now has something natalizumab does not: genuine head-to-head trial evidence against a comparator biologic. In the phase 3b VARSITY trial, vedolizumab outperformed adalimumab, one of the most widely used anti-TNF agents, on both clinical remission and endoscopic improvement in ulcerative colitis, a level of comparative evidence rarely available for any agent in this class. N Engl J MedSince 2023, the practical landscape has also grown more complex. A natalizumab biosimilar, Tyruko, entered the US market carrying the identical boxed warning and REMS obligations as its reference product. Tyruko PI Vedolizumab, meanwhile, gained a subcutaneous, self-administered option that most patients can now switch to after two initial infusions. Entyvio PIFor clinicians managing Crohn disease, where both alpha-4 integrin inhibitors are approved, and for those managing multiple sclerosis or ulcerative colitis, where only one is, the choice between these agents is no longer just a matter of indication. It is a question of which category of risk a given patient can tolerate, and what two decades of divergent safety data now make clear about that tradeoff.Key StatisticDetailClass footprint2 molecular mechanisms, 3 branded products, 3 FDA-approved conditions across 2 specialties, spanning 2004–2024. Tysabri PI +2Natalizumab PML risk (highest stratum)Up to 7 per 1,000 anti-JCV antibody–positive patients with prior immunosuppressant use after 49–72 months of treatment. Tysabri PIVARSITY head-to-head resultVedolizumab vs adalimumab in ulcerative colitis: clinical remission in 31.3% vs 22.5% at week 52 (P=.006). N Engl J MedDEEP DIVEAlpha-4 Integrin Inhibitors Across Neurology and GastroenterologyMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: Alpha-4 Integrin Inhibitors: Why Natalizumab's PML Warning and Vedolizumab's VARSITY Win Both Matter - Medscape- September 24, 2026.